Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 29, 2026, 11:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 35 matching trials from the live ClinicalTrials.gov search.
Active, not recruiting Not applicable Interventional

EPI-MINN: Targeting Cognition and Motivation - National

NCT05877716
Conditions
Psychosis, Psychosis Nos/Other, Schizophrenia, Schizo Affective Disorder, Schizoaffective Disorder, Prodromal Schizophrenia, Schizophrenia Spectrum and Other Psychotic Disorders, Schizophreniform Disorders, Major Depression With Psychotic Features, Unspecified Psychosis, Bipolar Disorder
Interventions
Cognitive and Social Cognitive Training, Personalized Real-Time Intervention for Motivational Enhancement (PRIME) App, Early Psychosis Coordinated Specialty Care
Device · Behavioral · Other
Lead sponsor
University of Minnesota
Other
Eligibility
15 Years to 40 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Affective Disorders, Psychotic, Depressive Disorder
Interventions
Mifepristone (RU-486), Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
21 Years to 85 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Stanford, California
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder With Psychotic Features, Major Depression With Psychotic Features, Psychotic Disorder Not Otherwise Specified (NOS)
Interventions
Group Cognitive Behavioral Therapy, Multifamily Group Psychoeducation
Behavioral
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 35 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Tucson, Arizona
Conditions
Depressive Disorder, Major
Interventions
Mifepristone
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
13
States / cities
San Diego, California • Atlanta, Georgia • Las Vegas, Nevada + 10 more
Conditions
Recent-Onset Psychosis, Schizophrenia, Schizoaffective Disorder, Bipolar Disorder With Psychotic Features, Major Depression With Psychotic Features, Psychotic Disorder Not Otherwise Specified (NOS)
Interventions
Multifamily Group Psychoeducation (MFG), Cognitive Remediation (CR)
Behavioral
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 35 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Tucson, Arizona
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder With Psychotic Features, Major Depression With Psychotic Features, Psychosis Not Otherwise Specified (NOS)
Interventions
Not listed
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Tucson, Arizona
Conditions
Major Depressive Disorder Without Psychotic Features
Interventions
Asenapine 5-20 mg daily, Placebo 1-4 tablets daily
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
5
States / cities
Augusta, Georgia • Durham, North Carolina • Greenville, North Carolina + 1 more
Completed Not applicable Interventional Results available

Psychosis: Early Detection, Intervention and Prevention

NCT01597141
Conditions
Prodromal Schizophrenia, Psychotic Disorders, Severe Bipolar Disorder With Psychotic Features, Severe Major Depression With Psychotic Features
Interventions
Family-aided Assertive Community Treatment, Enhanced standard treatment
Behavioral
Lead sponsor
MaineHealth
Other
Eligibility
12 Years to 35 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2014
U.S. locations
1
States / cities
Portland, Maine
Conditions
Psychotic Depression
Interventions
Aripiprazole
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Phase 3 Interventional Results available

Study of Pharmacotherapy of Psychotic Depression

NCT00056472
Conditions
Major Depressive Disorder With Psychotic Features
Interventions
Olanzapine, Sertraline, placebo
Drug · Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
259 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
3
States / cities
Worcester, Massachusetts • New York, New York • Pittsburgh, Pennsylvania
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depression With Psychotic Features
Interventions
Ending Self Stigma (ESS), Health and Wellness Group
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 80 Years
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland • Perry Point, Maryland
Completed No phase listed Observational Accepts healthy volunteers

Clinical and Biological Characteristics of Psychotic Depression

NCT00576095
Conditions
Depression, Psychotic Disorders, Depressive Disorder, Major
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 85 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2012
U.S. locations
1
States / cities
Stanford, California
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Psychotic Depression
Interventions
Recovery Mentor
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years to 80 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Major Depressive Disorder, Psychotic Disorders
Interventions
ORG 34517
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
New York, New York
Completed Not applicable Interventional Results available

Naltrexone for Antipsychotic-Induced Weight Gain

NCT01866098
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Bipolar Disorder, Severe Major Depression With Psychotic Features
Interventions
Naltrexone, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 75 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Schizophrenia, Schizoaffective Disorder, Delusional Disorder, Major Depressive Disorder With Psychotic Features
Interventions
Collaborative Decision Skills Training, Leveling Up
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
San Diego, California
Conditions
Major Depressive Disorder
Interventions
Olanzapine, Fluoxetine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
30
States / cities
Oceanside, California • San Marcos, California • Torrance, California + 27 more
Conditions
Major Depressive Disorder, Major Depressive Disorder w/ Psychotic Features, Metabolic Syndrome
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Treatment, Active Control, Schizophrenia, Psychosis, Schizoaffective Disorder, Psychotic Depression, Psychotic Mood Disorders, Psychotic Disorders, Psychotic Episode, Cognitive Impairment
Interventions
Structured Cognitive Training & PRIME, Computer Games Control & PRIME
Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 60 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
2
States / cities
San Francisco, California • Minneapolis, Minnesota
Recruiting No phase listed Observational

Transition Care for FEP

NCT07713849
Conditions
Schizoaffective Disorders, Bipolar Disorder With Psychotic Features, Schizophrenia Disorders, Major Depressive Disorder With Psychotic Features, Psychosis NOS
Interventions
Transition Care Team
Behavioral
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 40 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Chicago, Illinois • Harvey, Illinois
Conditions
Major Depression With Psychotic Features
Interventions
quetiapine
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Chicago, Illinois
Completed Not applicable Interventional

Academic-Community EPINET (AC-EPINET)

NCT04497857
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorders, Major Depression With Psychotic Features, Bipolar Disorder With Psychotic Features
Interventions
Coordinated Specialty Care (CSC)
Other
Lead sponsor
Indiana University
Other
Eligibility
16 Years to 35 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
6
States / cities
Indianapolis, Indiana • New Orleans, Louisiana • Ann Arbor, Michigan + 3 more
Conditions
Psychosis, Schizophrenia Disorder, Schizoaffective Disorder, Major Depressive Disorder With Psychotic Features, Bipolar Disorder With Psychotic Features, Psychosis NOS, Schizophreniform Disorder, Psychotic Disorder, Cognition
Interventions
Modafinil, D-serine solution, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 35 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Minneapolis, Minnesota
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Multi-modal Assessment of Gamma-aminobutyric Acid (GABA) Function in Psychosis

NCT04004416
Conditions
Schizophrenia, Bipolar Disorder, Healthy, Psychosis, Schizophreniform Disorders, Schizo Affective Disorder, Major Depression With Psychotic Features
Interventions
Placebo and fMRI, Lorazepam and fMRI
Other · Drug
Lead sponsor
University of Michigan
Other
Eligibility
16 Years to 60 Years
Enrollment
143 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
Ann Arbor, Michigan